Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

We aimed to identify the clinical characteristics related to increased nivolumab exposure in Japanese patients with renal cell carcinoma (RCC) in real-world clinical setting. Eleven patients were treated with the originally approved nivolumab dosing regimen of 3 mg/kg every 2 weeks (Q2W) (3-mg/kg gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Renpei, Ikarashi, Daiki, Matsuura, Tomohiko, Maekawa, Shigekatsu, Kato, Yoichiro, Kanehira, Mitsugu, Takata, Ryo, Tokuyama, Rie, Tamai, Kanako, Harigai, Naoto, Nakazaki, Yukoh, Obara, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205763/
https://www.ncbi.nlm.nih.gov/pubmed/32375081
http://dx.doi.org/10.1016/j.tranon.2020.100771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205763/
https://www.ncbi.nlm.nih.gov/pubmed/32375081
http://dx.doi.org/10.1016/j.tranon.2020.100771

Ejemplares similares